New drug combo targets Hard-to-Treat neuroendocrine tumors
NCT ID NCT05746208
First seen Mar 24, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study tests a combination of two drugs (lenvatinib and pembrolizumab) in people with a rare, aggressive type of neuroendocrine tumor called well-differentiated grade 3 (WD G3 NET). The goal is to see if the treatment can shrink or control the tumors. About 29 adults with advanced tumors that cannot be removed by surgery will take part. The study also uses special scans and blood tests to learn more about how the tumors respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.